The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease

European Journal of Haematology

Volumn 89, Issue 5, 2012, Pages 403-409

  Al Habboubi, Hebah H ^a   Mahdi, Najat ^b   Abu Hijleh, Tala M ^a   Abu Hijleh, Farah M ^a   Sater, Mai S ^a   Almawi, Wassim Y ^a  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

^b Salmaniya Medical Complex ^*  (Bahrain)

Author keywords

Sickle cell disease; Vascular endothelial growth factor; Vasoocclusive crisis

Indexed keywords

ADULT; ALLELE; ARTICLE; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR ENDOTHELIAL GROWTH FACTOR A GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE; VASOOCCLUSIVE CRISIS;

ADOLESCENT; ANEMIA, SICKLE CELL; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84867458482     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12003     Document Type: Article

References (29)

1. Pack-Mabien A, Haynes J Jr. A primary care provider's guide to preventive and acute care management of adults and children with sickle cell disease. J Am Acad Nurse Pract 2009;21:250-7.
2. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376:2018-31.
3. Sankaran VG, Lettre G, Orkin SH, Hirschhorn JN. Modifier genes in Mendelian disorders: the example of hemoglobin disorders. Ann NY Acad Sci 2010;1214:47-56.
4. Taha HM, Rehmani RS. Pain management of children and adolescents with sickle cell disease presenting to the emergency department. Saudi Med J 2011;32:152-5.
5. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000;96:2451-9.
6. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-83.
7. Ballas SK. Update on pain management in sickle cell disease. Hemoglobin 2011;35:520-9.
8. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood 1992;79:2154-63.
9. Shibuya M. Vascular endothelial growth factor (VEGF)-Receptor 2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 2006;13:63-9.
10. Ylä-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007;49:1015-26.
11. Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2010;2:165-75.
12. Galazios G, Papazoglou D, Tsikouras P, Kolios G. Vascular endothelial growth factor gene polymorphisms and pregnancy. J Matern Fetal Neonatal Med 2009;22:371-8.
13. Nourse MB, Halpin DE, Scatena M, Mortisen DJ, Tulloch NL, Hauch KD, Torok-Storb B, Ratner BD, Pabon L, Murry CE. VEGF induces differentiation of functional endothelium from human embryonic stem cells: implications for tissue engineering. Arterioscler Thromb Vasc Biol 2010;3:80-9.
14. Stannard AK, Khurana R, Evans IM, Sofra V, Holmes DI, Zachary I. Vascular endothelial growth factor synergistically enhances induction of E-selectin by tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 2007;27:494-502.
15. Kurtagic E, Jedrychowski MP, Nugent MA. Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity. Am J Physiol Lung Cell Mol Physiol 2009;296:534-46.
16. Uchida C, Haas TL. Evolving Strategies in Manipulating VEGF/VEGFR Signaling for the Promotion of Angiogenesis in Ischemic Muscle. Curr Pharm Des 2009;15:411-21.
17. Al-Khateeb GM, Mustafa FE, Issa AA, Finan RR, Almawi WY. Effect of the functional VEGFA -583C>T variant on VEGF levels and the risk of recurrent spontaneous miscarriage. Fertil Steril 2011;84:186-92.
18. Abhary S, Burdon KP, Gupta A, Lake S, Selva D, Petrovsky N, Craig JE. Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Invest Ophthalmol Vis Sci 2009;50:5552-8.
19. Vairaktaris E, Serefoglou Z, Avgoustidis D, et al. Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol 2009;45:247-53.
20. Gürkan E, Tanriverdi K, Başlamişli F. Clinical relevance of vascular endothelial growth factor levels in sickle cell disease. Ann Hematol 2005;84:71-5.
21. Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstein A, Coates TD, Kalra VK, Malik P. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood 2003;102:1506-14.
22. Elito J Jr, Daher S, Fernandes da Silva MO, Marconi NM, Pendeloski KP, Moron AF, Camano L. Association study of vascular endothelial growth factor and polymorphisms of its gene with ectopic pregnancy. Am J Reprod Immunol 2010;63:120-5.
23. Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010;117:109-16.
24. Ballis SK, Carlos TM, Dampier C. Guidelines for standard of care of acute painful episodes in patients with sickle cell disease. Harrisburg, PA: Commonwealth of Pennsylvania Department of Health, 1996.
25. Al-Habboubi HH, Sater MS, Almawi AW, Al-Khateeb GM, Almawi WY. Contribution of VEGF polymorphisms to variation in VEGF serum levels in a healthy population. Eur Cytokine Netw 2011;22:154-8.
26. Duits AJ, Rodriguez T, Schnog JJ, CURAMA Study Group. Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell disease. Br J Haematol 2006;134:116-19.
27. Mohammed FA, Mahdi N, Sater MA, Al-Ola K, Almawi WY. The relation of C-reactive protein to vasoocclusive crisis in children with sickle cell disease. Blood Cells Mol Dis 2010;45:293-6.
28. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest 2000;106:337-8.
29. Musa BO, Onyemelukwe GC, Hambolu JO, Mamman AI, Isa AH. Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis. Clin Vaccine Immunol 2010;17:602-8.